Identification

Name
Moexipril
Accession Number
DB00691  (APRD01120)
Type
Small Molecule
Groups
Approved
Description

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Structure
Thumb
Synonyms
  • Moexipril
  • Moexiprilum
External IDs
RS-10085
Product Ingredients
IngredientUNIICASInChI Key
Moexipril HydrochlorideQ1UMG3UH4582586-52-5JXRAXHBVZQZSIC-JKVLGAQCSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
UnivascTablet, film coated15 mg/1OralUcb Inc1995-07-152016-02-25Us
UnivascTablet, film coated7.5 mg/1OralUcb Inc1995-07-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Moexipril HydrochlorideTablet15 mg/1OralPhysicians Total Care, Inc.2004-04-27Not applicableUs
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralTeva2003-05-08Not applicableUs
Moexipril HydrochlorideTablet7.5 mg/1OralApotex Corporation2008-06-092018-05-11Us
Moexipril HydrochlorideTablet, film coated15 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2010-12-31Not applicableUs68462 0208 01 nlmimage10 7a1b3d59
Moexipril HydrochlorideTablet, film coated15 mg/1OralCarilion Materials Management2003-05-08Not applicableUs
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralCarilion Materials Management2003-05-08Not applicableUs00093 0017 01 nlmimage10 6629b33d
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralAvera Mc Kennan Hospital2015-08-102018-05-31Us
Moexipril HydrochlorideTablet7.5 mg/1OralPhysicians Total Care, Inc.2008-08-14Not applicableUs
Moexipril HydrochlorideTablet, film coated15 mg/1OralTeva2003-05-08Not applicableUs00093 5150 01 nlmimage10 2e29974c
Moexipril HydrochlorideTablet15 mg/1OralApotex Corporation2008-06-092018-05-11Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralGlenmark Pharmaceuticals Inc.,Usa2010-03-18Not applicableUs
Moexipril hydrochloride and hydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralHeritage2014-03-20Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralAv Kare, Inc.2017-04-03Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (7.5 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralGlenmark Pharmaceuticals Inc.,Usa2010-03-18Not applicableUs68462 0207 01 nlmimage10 37411ba8
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralTeva2007-03-07Not applicableUs00093 5214 01 nlmimage10 5a2bad7d
Moexipril hydrochloride and hydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralHeritage2014-03-20Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAv Kare, Inc.2017-04-03Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralGlenmark Pharmaceuticals Inc.,Usa2010-03-18Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (7.5 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralTeva2007-03-07Not applicableUs00093 5213 01 nlmimage10 632bb1fd
Moexipril hydrochloride and hydrochlorothiazideMoexipril Hydrochloride (7.5 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralHeritage2014-03-20Not applicableUs
International/Other Brands
Uniretic / Univasc
Categories
UNII
WT87C52TJZ
CAS number
103775-10-6
Weight
Average: 498.5681
Monoisotopic: 498.236601452
Chemical Formula
C27H34N2O7
InChI Key
UWWDHYUMIORJTA-HSQYWUDLSA-N
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension.

Associated Conditions
Pharmacodynamics

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Mechanism of action

Moexipril is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone). Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin hypertension.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
AAngiotensin-converting enzyme 2
inhibitor
Human
Absorption

Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40%, respectively, after the ingestion of a low-fat breakfast or by 80% and 50%, respectively, after the ingestion of a high-fat breakfast.

Volume of distribution
  • 183 L
Protein binding

Moexiprilat is approxomately 50% protein bound.

Metabolism

Rapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site.

Route of elimination

Moexiprilat undergoes renal elimination.

Half life

Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.

Clearance
  • 441 mL/min
Toxicity

Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. Common adverse effects include cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, and myalgia

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Moexipril Metabolism PathwayDrug metabolism
Moexipril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Moexipril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Moexipril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Moexipril.Approved, Investigational
AcebutololMoexipril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Moexipril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Moexipril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Moexipril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Moexipril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Moexipril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Moexipril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Moexipril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Moexipril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Moexipril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Moexipril.Approved
AloxiprinThe therapeutic efficacy of Moexipril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Moexipril.Approved, Illicit, Investigational
AlprenololMoexipril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanMoexipril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Moexipril.Experimental, Investigational
AmifostineMoexipril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Moexipril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Moexipril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Moexipril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Moexipril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneMoexipril may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Moexipril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Moexipril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Moexipril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Moexipril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Moexipril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Moexipril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Moexipril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Moexipril is combined with Amyl Nitrite.Approved
AnagrelideMoexipril may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Moexipril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Moexipril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Moexipril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Moexipril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Moexipril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Moexipril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Moexipril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Moexipril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Moexipril.Investigational
Arsenic trioxideMoexipril may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMoexipril may increase the QTc-prolonging activities of Artemether.Approved
AsenapineMoexipril may increase the QTc-prolonging activities of Asenapine.Approved
AtenololAtenolol may increase the hypotensive activities of Moexipril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Moexipril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Moexipril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Moexipril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Moexipril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Moexipril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Moexipril.Approved, Investigational
AzithromycinMoexipril may increase the QTc-prolonging activities of Azithromycin.Approved
AzosemideAzosemide may increase the hypotensive activities of Moexipril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Moexipril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Moexipril.Experimental
BarbitalBarbital may increase the hypotensive activities of Moexipril.Illicit
BarnidipineMoexipril may increase the antihypertensive activities of Barnidipine.Approved
BedaquilineMoexipril may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilBenazepril may increase the hypotensive activities of Moexipril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Moexipril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Moexipril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Moexipril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Moexipril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Moexipril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Moexipril.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Moexipril.Approved
BepridilMoexipril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Moexipril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Moexipril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Moexipril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Moexipril.Experimental
BimatoprostMoexipril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Moexipril.Approved
BoceprevirThe serum concentration of Moexipril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Moexipril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Moexipril.Approved, Investigational
BQ-123Moexipril may increase the hypotensive activities of BQ-123.Investigational
BretyliumMoexipril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Moexipril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Moexipril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Moexipril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Moexipril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Moexipril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Moexipril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Moexipril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Moexipril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Moexipril.Approved, Investigational
BupranololMoexipril may increase the hypotensive activities of Bupranolol.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Moexipril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Moexipril.Approved
CadralazineCadralazine may increase the hypotensive activities of Moexipril.Experimental
CafedrineMoexipril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Moexipril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Moexipril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Moexipril.Experimental
CaptoprilMoexipril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Moexipril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Moexipril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Moexipril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Moexipril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Moexipril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Moexipril.Approved
CarvedilolMoexipril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Moexipril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Moexipril.Approved, Investigational
CeliprololMoexipril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibMoexipril may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Moexipril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Moexipril.Approved, Vet Approved
ChlorpromazineMoexipril may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Moexipril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Moexipril.Approved
CicletanineMoexipril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMoexipril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Moexipril.Approved, Investigational
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Moexipril is combined with Ciprofloxacin.Approved, Investigational
CisaprideMoexipril may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMoexipril may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Moexipril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Moexipril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Moexipril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Moexipril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Moexipril.Approved
CloranololMoexipril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineMoexipril may increase the QTc-prolonging activities of Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Moexipril.Approved, Investigational
CrizotinibMoexipril may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineMoexipril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Moexipril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Moexipril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Moexipril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Moexipril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Moexipril.Approved, Investigational
DelaprilMoexipril may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Moexipril.Approved
DersalazineThe therapeutic efficacy of Moexipril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineMoexipril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Moexipril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Moexipril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Moexipril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Moexipril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Moexipril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Moexipril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineMoexipril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Moexipril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Moexipril.Experimental
DiflunisalThe therapeutic efficacy of Moexipril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Moexipril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Moexipril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Moexipril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Moexipril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Moexipril.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Dipyridamole.Approved
DisopyramideMoexipril may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideMoexipril may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronMoexipril may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneMoexipril may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideMoexipril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Moexipril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Moexipril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Moexipril.Approved, Investigational
DronedaroneMoexipril may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMoexipril may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneMoexipril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Moexipril.Withdrawn
DuloxetineMoexipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Moexipril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Moexipril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Moexipril.Investigational
EfonidipineMoexipril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatMoexipril may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Moexipril.Approved, Vet Approved
EnalaprilatMoexipril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Moexipril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Moexipril.Approved, Investigational
EpanololMoexipril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Moexipril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Moexipril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Moexipril.Approved
EpoprostenolMoexipril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Moexipril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Moexipril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Moexipril.Approved
ErythromycinMoexipril may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EscitalopramMoexipril may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Moexipril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Moexipril.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Moexipril.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Moexipril.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Moexipril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Moexipril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Moexipril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Moexipril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Moexipril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Moexipril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Moexipril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Moexipril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Moexipril.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Moexipril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Moexipril.Experimental
FelodipineMoexipril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Moexipril.Approved
FenoldopamMoexipril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Moexipril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Moexipril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Moexipril.Experimental
Ferulic acidMoexipril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Moexipril.Approved, Investigational
FlecainideMoexipril may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Moexipril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Moexipril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Moexipril.Experimental
FluoxetineMoexipril may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMoexipril may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Moexipril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Moexipril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Moexipril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Moexipril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Moexipril.Approved, Vet Approved
Gadobenic acidMoexipril may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GarlicThe serum concentration of Moexipril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GemifloxacinMoexipril may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinMoexipril may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMoexipril may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuacetisalThe therapeutic efficacy of Moexipril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Moexipril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Moexipril.Approved
GuanazodineMoexipril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMoexipril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Moexipril.Approved, Investigational
GuanoclorMoexipril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMoexipril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMoexipril may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolMoexipril may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Moexipril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Moexipril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Moexipril is combined with Heparin.Approved, Investigational
HexamethoniumMoexipril may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Moexipril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Moexipril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Moexipril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Moexipril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Moexipril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Moexipril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Moexipril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Moexipril.Withdrawn
IbutilideMoexipril may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Moexipril.Approved, Investigational
IloperidoneMoexipril may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Moexipril.Approved, Investigational
ImidaprilMoexipril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Moexipril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Moexipril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Moexipril.Approved
IndenololMoexipril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Moexipril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Moexipril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Moexipril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Moexipril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Moexipril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Moexipril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Moexipril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Moexipril.Approved, Investigational
IronIron can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Moexipril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Moexipril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Moexipril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Moexipril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Moexipril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Moexipril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Moexipril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Moexipril.Approved
LabetalolLabetalol may increase the hypotensive activities of Moexipril.Approved
LacidipineMoexipril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Moexipril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Moexipril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Moexipril.Approved, Investigational
LenvatinibMoexipril may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Moexipril.Approved, Investigational
LeuprolideMoexipril may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Moexipril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Moexipril.Approved, Investigational
LevodopaMoexipril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinMoexipril may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Moexipril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Moexipril.Approved
LinsidomineMoexipril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilMoexipril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Moexipril.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Moexipril.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Moexipril.Experimental
LofexidineMoexipril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Moexipril.Experimental
LopinavirMoexipril may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Moexipril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Moexipril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Moexipril.Approved, Investigational
LumefantrineMoexipril may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Moexipril.Approved, Investigational
MacitentanMoexipril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Moexipril.Approved
ManidipineMoexipril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Moexipril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Moexipril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Moexipril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Moexipril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Moexipril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Moexipril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Moexipril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Moexipril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Moexipril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Moexipril.Approved, Investigational, Withdrawn
MethadoneMoexipril may increase the QTc-prolonging activities of Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Moexipril.Approved
MethoserpidineMoexipril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Moexipril.Approved
Methyl salicylateThe therapeutic efficacy of Moexipril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMoexipril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Moexipril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Moexipril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Moexipril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Moexipril.Approved
MetipranololMoexipril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Moexipril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Moexipril.Approved, Investigational
MetyrosineMoexipril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMoexipril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Moexipril.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Moexipril.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Moexipril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Moexipril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Moexipril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Moexipril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Moexipril.Approved, Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Moexipril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Moexipril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Moexipril.Approved, Investigational
MoxifloxacinMoexipril may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Moexipril.Approved, Investigational
MuzolimineMoexipril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Moexipril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Moexipril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Moexipril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Moexipril.Approved
NadololMoexipril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Moexipril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Moexipril.Approved
NaftopidilMoexipril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Moexipril.Approved, Vet Approved
NebivololMoexipril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Moexipril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Moexipril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Moexipril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Moexipril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Moexipril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Moexipril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Moexipril.Approved
NiguldipineMoexipril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibMoexipril may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineMoexipril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Moexipril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Moexipril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Moexipril.Approved
NitrendipineMoexipril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Moexipril.Approved
NitroaspirinThe therapeutic efficacy of Moexipril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Moexipril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Moexipril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Moexipril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Moexipril.Approved
ObinutuzumabMoexipril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Moexipril.Withdrawn
OfloxacinMoexipril may increase the QTc-prolonging activities of Ofloxacin.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Moexipril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Moexipril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Moexipril.Approved
OmapatrilatMoexipril may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronMoexipril may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Moexipril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Moexipril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Moexipril.Approved
OxprenololMoexipril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Moexipril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moexipril.Approved, Vet Approved
PaliperidoneMoexipril may increase the QTc-prolonging activities of Paliperidone.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Moexipril.Experimental, Nutraceutical
PanobinostatMoexipril may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Moexipril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Moexipril.Approved
PargylinePargyline may increase the hypotensive activities of Moexipril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Moexipril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Moexipril can be decreased when used in combination with Patent Blue.Approved
PazopanibMoexipril may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololMoexipril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineMoexipril may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
PentoliniumMoexipril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Moexipril.Approved, Investigational
PerflutrenMoexipril may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilMoexipril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Moexipril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Moexipril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Moexipril.Approved, Investigational
PhenoxybenzamineMoexipril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Moexipril.Withdrawn
PhentolamineMoexipril may increase the hypotensive activities of Phentolamine.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Moexipril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Moexipril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Moexipril.Approved, Investigational
PimozideMoexipril may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Moexipril.Approved
PindololMoexipril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Moexipril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Moexipril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Moexipril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Moexipril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Moexipril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Moexipril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Moexipril.Withdrawn
Platelet Activating FactorMoexipril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Moexipril.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Moexipril.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Moexipril.Approved, Investigational
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Moexipril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Moexipril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Moexipril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Moexipril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Moexipril.Approved
PregabalinThe risk or severity of angioedema can be increased when Moexipril is combined with Pregabalin.Approved, Illicit, Investigational
PrimaquineMoexipril may increase the QTc-prolonging activities of Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Moexipril.Approved, Vet Approved
ProcainamideMoexipril may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Moexipril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Moexipril.Experimental
PromazineMoexipril may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Moexipril.Approved, Investigational
PropafenoneMoexipril may increase the QTc-prolonging activities of Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Moexipril.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Moexipril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Moexipril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Moexipril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Moexipril.Investigational
QuetiapineMoexipril may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilMoexipril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Moexipril.Approved
QuinidineMoexipril may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineMoexipril may increase the QTc-prolonging activities of Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Moexipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Moexipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Moexipril.Approved
RemikirenRemikiren may increase the hypotensive activities of Moexipril.Approved
RescinnamineMoexipril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Moexipril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Moexipril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Moexipril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Moexipril.Approved
RisperidoneMoexipril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMoexipril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Moexipril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Moexipril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Moexipril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Moexipril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Moexipril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Moexipril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Moexipril.Approved
Salicylic acidThe therapeutic efficacy of Moexipril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Moexipril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Moexipril.Experimental
SaquinavirMoexipril may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Moexipril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Moexipril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Moexipril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
SelexipagMoexipril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Moexipril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Moexipril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Moexipril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Moexipril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Moexipril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Moexipril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Moexipril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Moexipril.Approved, Investigational
SitaxentanMoexipril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Moexipril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicMoexipril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolMoexipril may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilMoexipril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Moexipril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Moexipril.Investigational
St. John's WortThe metabolism of Moexipril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Moexipril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Moexipril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Moexipril.Approved
SulfisoxazoleMoexipril may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Moexipril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Moexipril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Moexipril.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Moexipril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Moexipril.Approved, Investigational
TalinololMoexipril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Moexipril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Moexipril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Moexipril.Approved
TelavancinMoexipril may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMoexipril may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Moexipril.Approved, Investigational
TemocaprilMoexipril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Moexipril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Moexipril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Moexipril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Moexipril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Moexipril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Moexipril.Approved
TerlipressinMoexipril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineMoexipril may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetrahydropalmatineMoexipril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Moexipril.Approved, Investigational, Withdrawn
TheodrenalineMoexipril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Moexipril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Moexipril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Moexipril.Approved, Vet Approved
ThioridazineMoexipril may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Moexipril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Moexipril.Approved
TiboloneMoexipril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenMoexipril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Moexipril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Moexipril.Investigational
TipranavirThe serum concentration of Moexipril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Moexipril.Approved, Investigational
TolazolineMoexipril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moexipril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Moexipril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Moexipril.Approved
TolonidineMoexipril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Moexipril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Moexipril.Approved
TorasemideTorasemide may increase the hypotensive activities of Moexipril.Approved
ToremifeneMoexipril may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Moexipril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Moexipril.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Moexipril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Moexipril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Moexipril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Moexipril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Moexipril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Moexipril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Moexipril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Moexipril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Moexipril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Moexipril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Moexipril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Moexipril.Investigational
Trolamine salicylateThe therapeutic efficacy of Moexipril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Moexipril.Approved, Investigational
UnoprostoneMoexipril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Moexipril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Moexipril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Moexipril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril.Approved, Investigational
VandetanibMoexipril may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Moexipril.Approved
VemurafenibMoexipril may increase the QTc-prolonging activities of Vemurafenib.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Moexipril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Moexipril.Approved, Investigational
VincamineMoexipril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMoexipril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideMoexipril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMoexipril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Moexipril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Moexipril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Moexipril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Moexipril.Approved, Investigational, Withdrawn
ZiprasidoneMoexipril may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilMoexipril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Moexipril.Withdrawn
ZuclopenthixolMoexipril may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of moexipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of moexipril.
  • Moexipril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take moexipril one hour before or two hours after meals.

References

General References
  1. Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J: Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. Acta Cardiol. 2002 Feb;57(1):31-2. [PubMed:11918132]
  2. Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME: Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Cardiovasc Drugs Ther. 1998 Sep;12(4):409-14. [PubMed:9825188]
  3. Brogden RN, Wiseman LR: Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. [PubMed:9617599]
  4. Cawello W, Boekens H, Waitzinger J, Miller U: Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. Int J Clin Pharmacol Ther. 2002 Jan;40(1):9-17. [PubMed:11837383]
  5. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086]
  6. Chrysant SG, Chrysant GS: Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. [PubMed:15030263]
  7. Chrysant GS, Nguyen PK: Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. [PubMed:17583172]
  8. Grass GM, Morehead WT: Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989 Sep;6(9):759-65. [PubMed:2554270]
  9. Kalasz H, Petroianu G, Tekes K, Klebovich I, Ludanyi K, Gulyas Z: Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med Chem. 2007 Jan;3(1):101-6. [PubMed:17266629]
  10. Persson B, Stimpel M: Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol. 1996;50(4):259-64. [PubMed:8803515]
  11. Spinar J, Vitovec J: MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial. Int J Cardiol. 2005 Apr 20;100(2):199-206. [PubMed:15823625]
  12. Stimpel M, Koch B, Oparil S: Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998 May;89(4):271-6. [PubMed:9643274]
  13. White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998 May-Jun;18(3):588-99. [PubMed:9620109]
  14. White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM: Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol. 1995 Mar;35(3):233-8. [PubMed:7608310]
External Links
Human Metabolome Database
HMDB0014829
KEGG Compound
C07704
PubChem Compound
91270
PubChem Substance
46508441
ChemSpider
82418
BindingDB
50084673
ChEBI
6960
ChEMBL
CHEMBL1165
Therapeutic Targets Database
DAP000586
PharmGKB
PA164769059
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Moexipril
ATC Codes
C09BA13 — Moexipril and diureticsC09AA13 — Moexipril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
2CompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Glenmark generics ltd
  • Paddock laboratories inc
  • Teva pharmaceuticals usa inc
  • Schwarz pharma inc
Packagers
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Cobalt Pharmaceuticals Inc.
  • Glenmark Generics Ltd.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Paddock Labs
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Resource Optimization and Innovation LLC
  • Schwarz Pharma Inc.
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
TabletOral15 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral7.5 mg/1
Tablet, film coatedOral
Tablet, film coatedOral15 mg/1
Prices
Unit descriptionCostUnit
Univasc 15 mg tablet2.44USD tablet
Univasc 7.5 mg tablet2.13USD tablet
Moexipril hcl 15 mg tablet1.48USD tablet
Moexipril hcl 7.5 mg tablet1.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySoluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00585 mg/mLALOGPS
logP1.52ALOGPS
logP1.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.46ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area114.4 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity132.88 m3·mol-1ChemAxon
Polarizability53.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5775
Blood Brain Barrier-0.9022
Caco-2 permeable-0.7313
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.5919
P-glycoprotein inhibitor IIInhibitor0.8157
Renal organic cation transporterNon-inhibitor0.8146
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.8369
CYP450 3A4 substrateSubstrate0.7014
CYP450 1A2 substrateNon-inhibitor0.8205
CYP450 2C9 inhibitorNon-inhibitor0.5961
CYP450 2D6 inhibitorNon-inhibitor0.8261
CYP450 2C19 inhibitorNon-inhibitor0.6592
CYP450 3A4 inhibitorNon-inhibitor0.5935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6861
Ames testNon AMES toxic0.8358
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.9762
Rat acute toxicity2.5131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9715
hERG inhibition (predictor II)Inhibitor0.8751
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Tetrahydroisoquinolines / Anisoles / Alkyl aryl ethers / Aralkylamines / Fatty acid esters / Benzene and substituted derivatives / Dicarboxylic acids and derivatives
show 10 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Tetrahydroisoquinoline / Anisole / Alkyl aryl ether / Fatty acid ester / Aralkylamine
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
peptide (CHEBI:6960)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin...
Gene Name
ACE2
Uniprot ID
Q9BYF1
Uniprot Name
Angiotensin-converting enzyme 2
Molecular Weight
92462.4 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:35